Rapid Biopharma Response To COVID-19 Enabled By Decades Of R&D Investment, Firms Say

 
• By Cathy Kelly

Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.

Innovative idea in businessman hand
COVID-19 Innovation Will Build On Past Efforts

More from Pricing Debate

More from Market Access